Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM dexmedetomidine + midazolam for MRI sedation in children with autism
ChiCTR2300072302Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jun 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dexmedetomidine, midazolam and atropine in Autism Spectrum Disorder (ASD), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Success rate of sedation with the first dose of anesthesia. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
dexmedetomidinemidazolamatropine
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on ChiCTR2300072302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072302.